Severity: Warning
Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 197
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 197
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 271
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3145
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Objectives: To present the case of a patient with squamous cell carcinoma of the cervix who developed distal necrosis following treatment with gemcitabine, and to perform a literature review to assess the association between the cumulative dose of gemcitabine, diagnosis, and management of this complication.
Material And Methods: A 61 year old patient was treated with gemcitabine (total accumulated dose of 11,744 mg/m²) for metastatic disease at a private, nononcological, fourth level general hospital, where she was receiving outpatient management. She developed distal necrosis of the second finger on her right hand, leading to the discontinuation of gemcitabine and necessitating amputation of the affected finger. A search was conducted in Embase, Medline, and Lilacs for case reports and case series on gemcitabine induced distal necrosis. Data on dosage, diagnosis, and treatment were extracted.
Results: Fifteen case reports including 19 cases of distal necrosis were identified. The cumulative doses of gemcitabine ranged from 1,700 to 28,700 mg/m². Diagnosis was primarily clinical, supplemented by angiography and Doppler ultrasound; treatment included discontinuation of gemcitabine, initiation of vasodilators, anticoagulants, and symptomatic management.
Conclusions: It is essential to recognize vascular toxicity as a potential adverse effect of gemcitabine and to conduct appropriate risk stratification in patients with advanced cancer and multiple prior treatment lines. Increased monitoring for this adverse effect is warranted with the use of this medication.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812097 | PMC |
http://dx.doi.org/10.18597/rcog.4248 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!